EUVIMEDEUVIMED entdecken
Open Access

Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy

Teresa Cardoso Delgado iD, Celia Martín-Cuevas iD, Ana C Sánchez Hidalgo iD, Antonio Gil Gómez iD, Claudia M Rejano Gordillo iD, Jon Landa iD, Rocío Gallego Durán, Naroa Goikoetxea-Usandizaga, Irene González-Recio, Clàudia Gil-Pitarch iD, L Estefanía Zapata-Pavas iD, Jon Ander Barrenechea-Barrenechea iD und 12 weitere

Science Advances · 24.10.2025 · 11 (43)

DOI: 10.1126/sciadv.ady9758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 24.10.2025. Verfasst von Teresa Cardoso Delgado und 23 weiteren Autor:innen. Beteiligte Einrichtung: Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia…. Hauptthemen laut MEDLINE: RNA, Small Interfering, Liver, Fatty Liver, Brain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N -acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 ( CNNM4 ), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA- Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingLiverFatty LiverBrainAnimalsMiceDisease Models, AnimalMaleHippocampusNeurogenesisBehavior, Animal

Substanzen

RNA, Small Interfering

Autor:innen und Institutionen

  • Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
  • Metabolic Liver Disease Laboratory, Biobizkaia Health Research Institute, 48903 Barakaldo, Bizkaia, Spain.
  • IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
  • Centro de Investigación en Enfermedades Raras (CIBERer), 28029 Madrid, Spain.
  • Translational Psychiatry, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain.
  • Spanish Network for Research in Mental Health (CIBERSAM, ISCIII), 28029 Madrid, Spain.

ORCID-Profile: Teresa Cardoso Delgado, Celia Martín-Cuevas, Ana C Sánchez Hidalgo, Antonio Gil Gómez, Claudia M Rejano Gordillo, Jon Landa, Clàudia Gil-Pitarch, L Estefanía Zapata-Pavas, Jon Ander Barrenechea-Barrenechea, Carolina Conter, Luis Alfonso Martínez-Cruz, Víctor D Ramos Herrero, Rubén Nogueiras, Mikel Azkargorta, Felix Elortza, Javier Crespo, Manuel Romero Gómez, Benedicto Crespo-Facorro, María Luz Martínez-Chantar

Zitieren

APA

Cardoso Delgado, T., Martín-Cuevas, C., Sánchez Hidalgo, A. C., Gil Gómez, A., Rejano Gordillo, C. M., Landa, J., Gallego Durán, R., Goikoetxea-Usandizaga, N., González-Recio, I., Gil-Pitarch, C., Zapata-Pavas, L. E., Barrenechea-Barrenechea, J. A., Conter, C., Martínez-Cruz, L. A., Ramos Herrero, V. D., Nogueiras, R., Azkargorta, M., Elortza, F., Moncho-Amor, V., …, & Martínez-Chantar, M. L. (2025). Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy. Science Advances, 11(43). https://doi.org/10.1126/sciadv.ady9758

Vancouver

Cardoso Delgado T, Martín-Cuevas C, Sánchez Hidalgo AC, Gil Gómez A, Rejano Gordillo CM, Landa J, et al. Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy. Science Advances. 2025;11(43). doi:10.1126/sciadv.ady9758

BibTeX
@article{CardosoDelgado2025,
  author = {Cardoso Delgado, Teresa and Martín-Cuevas, Celia and Sánchez Hidalgo, Ana C and Gil Gómez, Antonio and Rejano Gordillo, Claudia M and Landa, Jon and Gallego Durán, Rocío and Goikoetxea-Usandizaga, Naroa and González-Recio, Irene and Gil-Pitarch, Clàudia and Zapata-Pavas, L Estefanía and Barrenechea-Barrenechea, Jon Ander and Conter, Carolina and Martínez-Cruz, Luis Alfonso and Ramos Herrero, Víctor D and Nogueiras, Rubén and Azkargorta, Mikel and Elortza, Felix and Moncho-Amor, Verónica and Crespo, Javier and Matheu, Ander and Romero Gómez, Manuel and Crespo-Facorro, Benedicto and Martínez-Chantar, María Luz},
  title = {Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {43},
  doi = {10.1126/sciadv.ady9758}
}
Kostenlos starten →